Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

Ear2MemoryFree App | Free PDF | Web
Learning languages on your smartphone
By BSK

Free Abstracts

  Lung Cancer

  Free Subscription


Articles published in Cancer Res

Retrieve available abstracts of 86 articles:
HTML format
Text format



Single Articles


    April 2017
  1. ICHIHARA E, Westover D, Meador CB, Yan Y, et al
    SFK/FAK signaling attenuates osimertinib efficacy in both drug-sensitive and drug-resistant models of EGFR-mutant lung cancer.
    Cancer Res. 2017 Apr 17. pii: canres.2300.2016.
    PubMed     Text format     Abstract available


  2. ZHANG Y, Xu W, Guo H, Zhang Y, et al
    NOTCH1 Signaling Regulates Self-renewal and Platinum Chemoresistance of Cancer Stem-like Cells in Human Non-small Cell Lung Cancer.
    Cancer Res. 2017 Apr 17. pii: canres.1633.2016.
    PubMed     Text format     Abstract available


  3. WEN H, Chiu YF, Kuo MH, Lee KL, et al
    Expression of neuroendocrine factor VGF in lung cancer cells confers resistance to EGFR kinase inhibitors and triggers epithelial-to-mesenchymal transition.
    Cancer Res. 2017 Apr 5. pii: canres.3168.2016.
    PubMed     Text format     Abstract available


    February 2017
  4. WANG M, Han J, Marcar L, Black J, et al
    Radiation resistance in KRAS-mutated lung cancer is enabled by stem-like properties mediated by an osteopontin-EGFR pathway.
    Cancer Res. 2017 Feb 15. pii: canres.0808.2016.
    PubMed     Text format     Abstract available


  5. ZHANG Y, Wei Y, Jiang B, Chen L, et al
    Scavenger receptor A1 prevents metastasis of non-small cell lung cancer via suppression of macrophage serum amyloid A1.
    Cancer Res. 2017 Feb 15. pii: canres.1569.2016.
    PubMed     Text format     Abstract available


  6. KAREKLA E, Liao WJ, Sharp B, Pugh J, et al
    Ex vivo explant cultures of non-small cell lung carcinoma enable evaluation of primary tumor responses to anticancer therapy.
    Cancer Res. 2017 Feb 15. pii: canres.1121.2016.
    PubMed     Text format     Abstract available


  7. NUKAGA S, Yasuda H, Tsuchihara K, Hamamoto J, et al
    Amplification of EGFR wild type alleles in non-small cell lung cancer cells confers acquired resistance to mutation-selective EGFR tyrosine kinase inhibitors.
    Cancer Res. 2017 Feb 15. pii: canres.2359.2016.
    PubMed     Text format     Abstract available


    January 2017
  8. KYUNG RHO J, Young Lee I, Jung Choi Y, Choi CM, et al
    Superior efficacy and selectivity of novel small molecule kinase inhibitors of T790M mutant EGFR in preclinical models of lung cancer.
    Cancer Res. 2017 Jan 12. pii: canres.2432.2016.
    PubMed     Text format     Abstract available


    December 2016
  9. TASSI E, Grazia G, Vegetti C, Bersani I, et al
    Early effector T lymphocytes coexpress multiple inhibitory receptors in primary non-small cell lung cancer.
    Cancer Res. 2016 Dec 15. pii: canres.1387.2016.
    PubMed     Text format     Abstract available


  10. UDYAVAR AR, Wooten DJ, Hoeksema MD, Bansal M, et al
    Novel hybrid phenotype revealed in Small Cell Lung Cancer by a transcription factor network model that can explain tumor heterogeneity.
    Cancer Res. 2016 Dec 8. pii: canres.1467.2016.
    PubMed     Text format     Abstract available


    October 2016
  11. SCHELHAAS S, Held A, Wachsmuth L, Hermann S, et al
    Gemcitabine Mechanism of Action Confounds Early Assessment of Treatment Response by 3'-Deoxy-3'-[18F]Fluorothymidine in Preclinical Models of Lung Cancer.
    Cancer Res. 2016 Oct 26. pii: canres.1479.2016.
    PubMed     Text format     Abstract available


    September 2016
  12. UM SW, Joung JG, Lee H, Kim H, et al
    Molecular evolution patterns in metastatic lymph nodes reflect the differential treatment response of advanced primary lung cancer.
    Cancer Res. 2016 Sep 13. pii: canres.0873.2016.
    PubMed     Text format     Abstract available


    August 2016
  13. BAGHDADI M, Wada H, Nakanishi S, Abe H, et al
    Chemotherapy-induced IL-34 enhances immunosuppression by tumor-associated macrophages and mediates survival of chemoresistant lung cancer cells.
    Cancer Res. 2016 Aug 22. pii: canres.1170.2016.
    PubMed     Text format     Abstract available


  14. YASUFUKU K, Jin CS, Wada H, Anayama T, et al
    An integrated nanotechnology-enabled transbronchial image-guided intervention strategy for peripheral lung cancer.
    Cancer Res. 2016 Aug 19. pii: canres.3196.2015.
    PubMed     Text format     Abstract available


  15. PATEL YM, Park SL, Han Y, Wilkens LR, et al
    Novel Association of Genetic Markers Affecting CYP2A6 activity and Lung Cancer Risk.
    Cancer Res. 2016 Aug 3. pii: canres.0446.2016.
    PubMed     Text format     Abstract available


    June 2016
  16. HALL Z, Ament Z, Wilson CH, Burkhart DL, et al
    Myc expression drives aberrant lipid metabolism in lung cancer.
    Cancer Res. 2016 Jun 22. pii: canres.3403.2015.
    PubMed     Text format     Abstract available


  17. OH AY, Jung YS, Kim J, Lee JH, et al
    Inhibiting DX2-p14/ARF interaction exerts antitumor effects in lung cancer and delays tumor progression.
    Cancer Res. 2016 Jun 14. pii: canres.1025.2015.
    PubMed     Text format     Abstract available


  18. CHALLA S, Guo J, Ding X, Xu CX, et al
    IKBKE is a substrate of EGFR and a therapeutic target in non-small cell lung cancer with activating mutations of EGFR.
    Cancer Res. 2016 Jun 10. pii: canres.0069.2016.
    PubMed     Text format     Abstract available


    May 2016
  19. MARWITZ S, Depner S, Dvornikov D, Merkle R, et al
    Downregulation of the TGF-beta pseudoreceptor BAMBI in non-small cell lung cancer enhances TGF-beta signaling and invasion.
    Cancer Res. 2016 May 17. pii: canres.1326.2015.
    PubMed     Text format     Abstract available


    April 2016
  20. CAETANO MS, Zhang H, Cumpian AM, Gong L, et al
    IL6 Blockade Reprograms the Lung Tumor Microenvironment to Limit the Development and Progression of K-ras-Mutant Lung Cancer.
    Cancer Res. 2016.
    PubMed     Text format     Abstract available


  21. BOUTET M, Gauthier L, Leclerc M, Gros G, et al
    TGFbeta Signaling Intersects with CD103 Integrin Signaling to Promote T-Lymphocyte Accumulation and Antitumor Activity in the Lung Tumor Microenvironment.
    Cancer Res. 2016;76:1757-69.
    PubMed     Text format     Abstract available


  22. FUCIKOVA J, Becht E, Iribarren K, Goc J, et al
    Calreticulin Expression in Human Non-Small Cell Lung Cancers Correlates with Increased Accumulation of Antitumor Immune Cells and Favorable Prognosis.
    Cancer Res. 2016;76:1746-56.
    PubMed     Text format     Abstract available


    March 2016
  23. LIU Y, Amin EB, Mayo MW, Chudgar NP, et al
    CK2alpha' Drives Lung Cancer Metastasis by Targeting BRMS1 Nuclear Export and Degradation.
    Cancer Res. 2016 Mar 15. pii: canres.2888.2015.
    PubMed     Text format     Abstract available


  24. BOUILLEZ A, Rajabi H, Pitroda S, Jin C, et al
    Inhibition of MUC1-C Suppresses MYC Expression and Attenuates Malignant Growth in KRAS Mutant Lung Adenocarcinomas.
    Cancer Res. 2016;76:1538-48.
    PubMed     Text format     Abstract available


  25. JOHNSON N, De Ieso P, Migliorini G, Orr N, et al
    Cytochrome P450 Allele CYP3A7*1C Associates with Adverse Outcomes in Chronic Lymphocytic Leukemia, Breast, and Lung Cancer.
    Cancer Res. 2016.
    PubMed     Text format     Abstract available


  26. KOYAMA S, Akbay EA, Li YY, Aref AR, et al
    STK11/LKB1 Deficiency Promotes Neutrophil Recruitment and Proinflammatory Cytokine Production to Suppress T-cell Activity in the Lung Tumor Microenvironment.
    Cancer Res. 2016;76:999-1008.
    PubMed     Text format     Abstract available


  27. CHOI SH, Nam JK, Kim BY, Jang J, et al
    HSPB1 Inhibits the Endothelial-to-Mesenchymal Transition to Suppress Pulmonary Fibrosis and Lung Tumorigenesis.
    Cancer Res. 2016;76:1019-30.
    PubMed     Text format     Abstract available


    February 2016
  28. BROOKS GD, McLeod L, Alhayyani S, Miller A, et al
    IL6 Trans-signaling Promotes KRAS-Driven Lung Carcinogenesis.
    Cancer Res. 2016;76:866-76.
    PubMed     Text format     Abstract available


  29. MURAYAMA T, Nakaoku T, Enari M, Nishimura T, et al
    Oncogenic Fusion Gene CD74-NRG1 Confers Cancer Stem Cell-like Properties in Lung Cancer through a IGF2 Autocrine/Paracrine Circuit.
    Cancer Res. 2016.
    PubMed     Text format     Abstract available


  30. FUJITA H, Nagakawa K, Kobuchi H, Ogino T, et al
    Phytoestrogen suppresses efflux of the diagnostic marker protoporphyrin IX (PpIX) in lung carcinoma.
    Cancer Res. 2016 Feb 2. pii: canres.1484.2015.
    PubMed     Text format     Abstract available


  31. BRENTVILLE VA, Metheringham RL, Gunn B, Symonds P, et al
    Citrullinated Vimentin Presented on MHC-II in Tumor Cells Is a Target for CD4+ T-Cell-Mediated Antitumor Immunity.
    Cancer Res. 2016;76:548-60.
    PubMed     Text format     Abstract available


  32. LI M, Kales SC, Ma K, Shoemaker BA, et al
    Balancing Protein Stability and Activity in Cancer: A New Approach for Identifying Driver Mutations Affecting CBL Ubiquitin Ligase Activation.
    Cancer Res. 2016;76:561-71.
    PubMed     Text format     Abstract available


    January 2016
  33. JIA Y, Juarez J, Li J, Manuia M, et al
    EGF816 exerts anticancer effects in non-small cell lung cancer by irreversibly and selectively targeting primary and acquired activating mutations in the EGF receptor.
    Cancer Res. 2016 Jan 29. pii: canres.2581.2015.
    PubMed     Text format     Abstract available


  34. YAN J, Ojo D, Kapoor A, Lin X, et al
    Neural cell adhesion protein CNTN1 promotes the metastatic progression of prostate cancer.
    Cancer Res. 2016 Jan 21. pii: canres.1898.2015.
    PubMed     Text format     Abstract available


  35. OHAR JA, Cheung M, Talarchek J, Howard SE, et al
    Germline BAP1 Mutational Landscape of Asbestos-Exposed Malignant Mesothelioma Patients with Family History of Cancer.
    Cancer Res. 2016;76:206-15.
    PubMed     Text format     Abstract available


  36. DE RIENZO A, Archer MA, Yeap BY, Dao N, et al
    Gender-Specific Molecular and Clinical Features Underlie Malignant Pleural Mesothelioma.
    Cancer Res. 2016;76:319-28.
    PubMed     Text format     Abstract available


  37. MEIER C, Hardtstock P, Joost S, Alla V, et al
    p73 and IGF1R Regulate Emergence of Aggressive Cancer Stem-like Features via miR-885-5p Control.
    Cancer Res. 2016;76:197-205.
    PubMed     Text format     Abstract available


  38. DUBOIS F, Keller M, Calvayrac O, Soncin F, et al
    RASSF1A suppresses the invasion and metastatic potential of human non-small cell lung cancer cells by inhibiting YAP activation through the GEF-H1/RhoB pathway.
    Cancer Res. 2016 Jan 12. pii: canres.1008.2015.
    PubMed     Text format     Abstract available


  39. AMATO KR, Wang S, Tan L, Hastings AK, et al
    EPHA2 Blockade Overcomes Acquired Resistance to EGFR Kinase Inhibitors in Lung Cancer.
    Cancer Res. 2016.
    PubMed     Text format     Abstract available


    December 2015
  40. ISOZAKI H, Ichihara E, Takigawa N, Ohashi K, et al
    Non-small cell lung cancer cells acquire resistance to the ALK inhibitor alectinib by activating alternative receptor tyrosine kinases.
    Cancer Res. 2015 Dec 30. pii: canres.1010.2015.
    PubMed     Text format     Abstract available


  41. RIQUELME E, Behrens C, Lin HY, Simon GR, et al
    Modulation of EZH2 expression by MEK-ERK or PI3K-AKT signaling in lung cancer is dictated by different KRAS oncogene mutations.
    Cancer Res. 2015 Dec 16. pii: canres.1141.2015.
    PubMed     Text format     Abstract available


  42. LASTWIKA KJ, Wilson W 3rd, Li QK, Norris J, et al
    Control of PD-L1 expression by oncogenic activation of the AKT/mTOR pathway in non-small cell lung cancer.
    Cancer Res. 2015 Dec 4. pii: canres.3362.2014.
    PubMed     Text format     Abstract available


    November 2015
  43. MOMCILOVIC M, McMickle R, Abt E, Seki A, et al
    Heightening Energetic Stress Selectively Targets LKB1-Deficient Non-Small Cell Lung Cancers.
    Cancer Res. 2015;75:4910-22.
    PubMed     Text format     Abstract available


  44. LANZARDO S, Conti L, Rooke R, Ruiu R, et al
    Immunotargeting of antigen xCT attenuates stem-like cell behavior and metastatic progression in breast cancer.
    Cancer Res. 2015 Nov 13. pii: canres.1208.2015.
    PubMed     Text format     Abstract available


  45. CHOI JW, Kim JK, Yang YJ, Kim P, et al
    Urokinase exerts antimetastatic effects by dissociating clusters of circulating tumor cells.
    Cancer Res. 2015;75:4474-82.
    PubMed     Text format     Abstract available


  46. ZHANG W, Gao Y, Li F, Tong X, et al
    YAP promotes malignant progression of Lkb1-deficient lung adenocarcinoma through downstream regulation of survivin.
    Cancer Res. 2015;75:4450-7.
    PubMed     Text format     Abstract available


  47. ELKIN SR, Bendris N, Reis CR, Zhou Y, et al
    A systematic analysis reveals heterogeneous changes in the endocytic activities of cancer cells.
    Cancer Res. 2015;75:4640-50.
    PubMed     Text format     Abstract available


    October 2015
  48. LANTERMANN AB, Chen D, McCutcheon KJ, Hoffman GR, et al
    Inhibition of casein kinase 1 alpha prevents acquired drug resistance to erlotinib in EGFR-mutant non-small cell lung cancer.
    Cancer Res. 2015 Oct 21. pii: canres.1113.2015.
    PubMed     Text format     Abstract available


  49. HAM B, Wang N, D'Costa Z, Fernandez MC, et al
    TNF receptor-2 facilitates an immunosuppressive microenvironment in the liver to promote the colonization and growth of hepatic metastases.
    Cancer Res. 2015 Oct 19. pii: canres.3173.2014.
    PubMed     Text format     Abstract available


  50. SOUCHERAY M, Capelletti M, Pulido I, Kuang Y, et al
    Intratumoral Heterogeneity in EGFR-Mutant NSCLC Results in Divergent Resistance Mechanisms in Response to EGFR Tyrosine Kinase Inhibition.
    Cancer Res. 2015;75:4372-83.
    PubMed     Text format     Abstract available


  51. YAMADA T, Amann JM, Fukuda K, Takeuchi S, et al
    Akt Kinase-Interacting Protein 1 Signals through CREB to Drive Diffuse Malignant Mesothelioma.
    Cancer Res. 2015;75:4188-97.
    PubMed     Text format     Abstract available


    September 2015
  52. BIKTASOVA AK, Dudimah DF, Uzhachenko RV, Park K, et al
    Multivalent forms of the Notch ligand DLL-1 enhance antitumor T cell immunity in lung cancer and improve efficacy of EGFR targeted therapy.
    Cancer Res. 2015 Sep 24. pii: canres.1154.2014.
    PubMed     Text format     Abstract available


  53. JACOB LS, Vanharanta S, Obenauf AC, Pirun M, et al
    Metastatic Competence Can Emerge with Selection of Preexisting Oncogenic Alleles without a Need of New Mutations.
    Cancer Res. 2015;75:3713-9.
    PubMed     Text format     Abstract available


  54. VANGAMUDI B, Paul TA, Shah PK, Kost-Alimova M, et al
    The SMARCA2/4 ATPase Domain Surpasses the Bromodomain as a Drug Target in SWI/SNF-Mutant Cancers: Insights from cDNA Rescue and PFI-3 Inhibitor Studies.
    Cancer Res. 2015;75:3865-78.
    PubMed     Text format     Abstract available


  55. ZHAN QM, Chen J, Lan T, Zhang W, et al
    Feed forward reciprocal activation of PAFR and STAT3 regulates epithelial-mesenchymal transition in non-small cell lung cancer.
    Cancer Res. 2015 Sep 10. pii: canres.1062.2015.
    PubMed     Text format     Abstract available


  56. ZHANG X, Yu X, Jiang G, Miao Y, et al
    Cytosolic TMEM88 promotes invasion and metastasis in lung cancer cells by binding DVLS.
    Cancer Res. 2015 Sep 10. pii: canres.3828.2015.
    PubMed     Text format     Abstract available


  57. SINGLETON KR, Hinz TK, Kleczko EK, Marek LA, et al
    Kinome RNAi Screens Reveal Synergistic Targeting of MTOR and FGFR1 Pathways as an Effective Strategy for Treatment of Lung Cancer and HNSCC.
    Cancer Res. 2015 Sep 10. pii: canres.0509.2015.
    PubMed     Text format     Abstract available


  58. GUO G, Gong K, Wohlfeld B, Hatanpaa KJ, et al
    Ligand-Independent EGFR Signaling.
    Cancer Res. 2015;75:3436-41.
    PubMed     Text format     Abstract available


    August 2015
  59. ZHANG Q, Qin J, Zhong L, Gong L, et al
    CCL5-mediated Th2 immune polarization promotes metastasis in luminal breast cancer.
    Cancer Res. 2015 Aug 6. pii: canres.3590.2014.
    PubMed     Text format     Abstract available


  60. LENG S, Wu G, Collins LB, Thomas CL, et al
    Implication of a Chromosome 15q15.2 Locus in Regulating UBR1 and Predisposing Smokers to MGMT Methylation in Lung.
    Cancer Res. 2015;75:3108-17.
    PubMed     Text format     Abstract available


  61. TANIZAKI J, Ercan D, Capelletti M, Dodge M, et al
    Identification of Oncogenic and Drug-Sensitizing Mutations in the Extracellular Domain of FGFR2.
    Cancer Res. 2015;75:3139-46.
    PubMed     Text format     Abstract available


  62. SHAI A, Dankort D, Juan J, Green S, et al
    TP53 Silencing Bypasses Growth Arrest of BRAFV600E-Induced Lung Tumor Cells in a Two-Switch Model of Lung Tumorigenesis.
    Cancer Res. 2015;75:3167-80.
    PubMed     Text format     Abstract available


    July 2015
  63. SIMO-RIUDALBAS L, Perez-Salvia M, Setien F, Villanueva A, et al
    KAT6B is a tumor suppressor histone H3 lysine 23 acetyltransferase undergoing genomic loss in small cell lung cancer.
    Cancer Res. 2015 Jul 24. pii: canres.3702.2014.
    PubMed     Text format     Abstract available


  64. TUCKER ER, Danielson LS, Innocenti P, Chesler L, et al
    Tackling Crizotinib Resistance: The Pathway from Drug Discovery to the Pediatric Clinic.
    Cancer Res. 2015;75:2770-4.
    PubMed     Text format     Abstract available


  65. AMIN AD, Rajan SS, Liang WS, Pongtornpipat P, et al
    Evidence Suggesting That Discontinuous Dosing of ALK Kinase Inhibitors May Prolong Control of ALK+ Tumors.
    Cancer Res. 2015;75:2916-27.
    PubMed     Text format     Abstract available


  66. BERTOLINI G, D'Amico L, Moro M, Landoni E, et al
    Microenvironment modulated metastatic CD133+/CXCR4+/EpCAM- lung cancer initiating cells sustain tumor dissemination and correlate with poor prognosis.
    Cancer Res. 2015 Jul 3. pii: canres.3781.2014.
    PubMed     Text format     Abstract available


    June 2015
  67. KAPOOR V, Khudanyan A, de la Puente P, Campian J, et al
    Stem cell transfusion restores immune function in radiation-induced lymphopenic C57/BL6 mice.
    Cancer Res. 2015 Jun 30. pii: canres.1412.2015.
    PubMed     Text format     Abstract available


  68. QU Z, Sun F, Zhou J, Li L, et al
    Interleukin-6 prevents the initiation but enhances the progression of lung cancer.
    Cancer Res. 2015 Jun 29. pii: canres.3042.2014.
    PubMed     Text format     Abstract available


  69. CHANG YW, Su YJ, Hsiao M, Wei KC, et al
    Diverse Targets of beta-catenin during the Epithelial-Mesenchymal Transition Define Cancer Stem Cells and Predict Disease Relapse.
    Cancer Res. 2015 Jun 29. pii: canres.3265.2014.
    PubMed     Text format     Abstract available


  70. GALLAGHER-COLOMBO SM, Miller J, Cengel KA, Putt ME, et al
    Erlotinib pretreatment improves photodynamic therapy of non-small cell lung carcinoma xenografts via multiple mechanisms.
    Cancer Res. 2015 Jun 8. pii: canres.3304.2014.
    PubMed     Text format     Abstract available


  71. SAITO M, Shimada Y, Shiraishi K, Sakamoto H, et al
    Development of lung adenocarcinomas with exclusive dependence on oncogene fusions.
    Cancer Res. 2015;75:2264-71.
    PubMed     Text format     Abstract available


  72. MUMBLAT Y, Kessler O, Ilan N, Neufeld G, et al
    Full-Length Semaphorin-3C Is an Inhibitor of Tumor Lymphangiogenesis and Metastasis.
    Cancer Res. 2015;75:2177-86.
    PubMed     Text format     Abstract available


    May 2015
  73. BORCHERDING N, Kusner D, Kolb R, Xie Q, et al
    Paracrine WNT5A Signaling Inhibits Expansion of Tumor-Initiating Cells.
    Cancer Res. 2015;75:1972-82.
    PubMed     Text format     Abstract available


  74. SCHLIEKELMAN MJ, Taguchi A, Zhu J, Dai X, et al
    Molecular portraits of epithelial, mesenchymal, and hybrid States in lung adenocarcinoma and their relevance to survival.
    Cancer Res. 2015;75:1789-800.
    PubMed     Text format     Abstract available


  75. ZHONG S, Yin H, Liao Y, Yao F, et al
    Lung Tumor Suppressor GPRC5A Binds EGFR and Restrains Its Effector Signaling.
    Cancer Res. 2015;75:1801-14.
    PubMed     Text format     Abstract available


    April 2015
  76. SHVEDOVA AA, Kisin ER, Yanamala N, Tkach AV, et al
    MDSC and TGFbeta Are Required for Facilitation of Tumor Growth in the Lungs of Mice Exposed to Carbon Nanotubes.
    Cancer Res. 2015;75:1615-23.
    PubMed     Text format     Abstract available


  77. ZAYNAGETDINOV R, Sherrill TP, Gleaves LA, McLoed AG, et al
    Interleukin-5 facilitates lung metastasis by modulating the immune microenvironment.
    Cancer Res. 2015;75:1624-34.
    PubMed     Text format     Abstract available


  78. BONASTRE E, Verdura S, Zondervan I, Facchinetti F, et al
    PARD3 Inactivation in Lung Squamous Cell Carcinomas Impairs STAT3 and Promotes Malignant Invasion.
    Cancer Res. 2015;75:1287-97.
    PubMed     Text format     Abstract available


  79. RICE WL, Shcherbakova DM, Verkhusha VV, Kumar AT, et al
    In vivo tomographic imaging of deep-seated cancer using fluorescence lifetime contrast.
    Cancer Res. 2015;75:1236-43.
    PubMed     Text format     Abstract available


    March 2015
  80. PILLAI S, Trevino J, Rawal B, Singh S, et al
    beta-arrestin-1 mediates nicotine-induced metastasis through E2F1 target genes that modulate epithelial-mesenchymal transition.
    Cancer Res. 2015;75:1009-20.
    PubMed     Text format     Abstract available


  81. SONG X, Fan PD, Bantikassegn A, Guha U, et al
    ERBB3-independent activation of the PI3K pathway in EGFR-mutant lung adenocarcinomas.
    Cancer Res. 2015;75:1035-45.
    PubMed     Text format     Abstract available


    February 2015
  82. JIANG F, Chen L, Yang YC, Wang XM, et al
    CYP3A5 Functions as a Tumor Suppressor in Hepatocellular Carcinoma by Regulating mTORC2/Akt Signaling.
    Cancer Res. 2015 Feb 3. pii: canres.1589.2014.
    PubMed     Text format     Abstract available


    January 2015
  83. YU J, Wang Y, Liu C, Luo M, et al
    Chemotherapy-induced miRNA-29c/catenin-delta signaling suppresses metastasis in gastric cancer.
    Cancer Res. 2015 Jan 29. pii: canres.0787.2014.
    PubMed     Text format     Abstract available


  84. NESKEY DM, Osman AA, Ow TJ, Katsonis P, et al
    Evolutionary Action score of TP53 (EAp53) identifies high risk mutations associated with decreased survival and increased distant metastases in head and neck cancer.
    Cancer Res. 2015 Jan 29. pii: canres.2735.2014.
    PubMed     Text format     Abstract available


  85. PETTERSSON F, Del Rincon SV, Emond A, Huor B, et al
    Genetic and pharmacologic inhibition of eIF4E reduces breast cancer cell migration, invasion and metastasis.
    Cancer Res. 2015 Jan 21. pii: canres.1996.2014.
    PubMed     Text format     Abstract available


    December 2014
  86. MA B, Herzog EL, Lee CG, Peng X, et al
    Role of Chitinase 3-like-1 and Semaphorin 7A in Pulmonary Melanoma Metastasis.
    Cancer Res. 2014 Dec 15. pii: canres.3339.2013.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Lung Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: